临床眼科杂志
臨床眼科雜誌
림상안과잡지
JOURNAL OF CLINICAL OPHTHALMOLOGY
2014年
6期
543-545
,共3页
新生血管性青光眼%玻璃体腔注射%雷珠单抗%小梁切除术
新生血管性青光眼%玻璃體腔註射%雷珠單抗%小樑切除術
신생혈관성청광안%파리체강주사%뢰주단항%소량절제술
Neovascular glaucoma%Intravitreal%Lucentis%Trabeculectomy%Mitomycin C
目的：观察玻璃体腔注射雷珠单抗（ Lucentis ）联合复合式小梁切除术治疗新生血管性青光眼的疗效。方法对17例（17只眼）新生血管性青光眼行玻璃体腔注射Lucentis 0．50 mg／0．05 ml，8～14 d后行复合式小梁切除术。观察玻璃体腔注射Lucentis 后虹膜及房角新生血管消退的时间、眼压的变化以及复合式小梁切除术后视力和眼压的变化。术后随访8～12个月。结果玻璃体腔注射Lucentis后，13只眼虹膜新生血管1周内完全消退，4只眼2二周内完全消退。注药前平均眼压（39．56±10．12） mm Hg，注药后1周平均眼压（38．62±8．35） mm Hg与注药前比较眼压变化无统计学意义（ t ＝0．951， P ＞0．05）。小梁切除术后1周眼压（10．43±6．12） mm Hg，最后一次随访眼压（13．61±4．31） mm Hg，与术前比较差异均有统计学意义（ t ＝21．362、19．817， P均﹤0．01）。末次随访时12只眼视力提高，5只眼视力未变。结论玻璃体腔注射雷珠单抗联合复合式小梁切除术能有效地控制眼压，保护视功能。
目的：觀察玻璃體腔註射雷珠單抗（ Lucentis ）聯閤複閤式小樑切除術治療新生血管性青光眼的療效。方法對17例（17隻眼）新生血管性青光眼行玻璃體腔註射Lucentis 0．50 mg／0．05 ml，8～14 d後行複閤式小樑切除術。觀察玻璃體腔註射Lucentis 後虹膜及房角新生血管消退的時間、眼壓的變化以及複閤式小樑切除術後視力和眼壓的變化。術後隨訪8～12箇月。結果玻璃體腔註射Lucentis後，13隻眼虹膜新生血管1週內完全消退，4隻眼2二週內完全消退。註藥前平均眼壓（39．56±10．12） mm Hg，註藥後1週平均眼壓（38．62±8．35） mm Hg與註藥前比較眼壓變化無統計學意義（ t ＝0．951， P ＞0．05）。小樑切除術後1週眼壓（10．43±6．12） mm Hg，最後一次隨訪眼壓（13．61±4．31） mm Hg，與術前比較差異均有統計學意義（ t ＝21．362、19．817， P均﹤0．01）。末次隨訪時12隻眼視力提高，5隻眼視力未變。結論玻璃體腔註射雷珠單抗聯閤複閤式小樑切除術能有效地控製眼壓，保護視功能。
목적：관찰파리체강주사뢰주단항（ Lucentis ）연합복합식소량절제술치료신생혈관성청광안적료효。방법대17례（17지안）신생혈관성청광안행파리체강주사Lucentis 0．50 mg／0．05 ml，8～14 d후행복합식소량절제술。관찰파리체강주사Lucentis 후홍막급방각신생혈관소퇴적시간、안압적변화이급복합식소량절제술후시력화안압적변화。술후수방8～12개월。결과파리체강주사Lucentis후，13지안홍막신생혈관1주내완전소퇴，4지안2이주내완전소퇴。주약전평균안압（39．56±10．12） mm Hg，주약후1주평균안압（38．62±8．35） mm Hg여주약전비교안압변화무통계학의의（ t ＝0．951， P ＞0．05）。소량절제술후1주안압（10．43±6．12） mm Hg，최후일차수방안압（13．61±4．31） mm Hg，여술전비교차이균유통계학의의（ t ＝21．362、19．817， P균﹤0．01）。말차수방시12지안시력제고，5지안시력미변。결론파리체강주사뢰주단항연합복합식소량절제술능유효지공제안압，보호시공능。
Objective To observe the effect of Lucentis intravitreous injection combined with trabeculectomy and MMC administration on neovascular glaucoma ( NVG) .Methods Seventeen eyes of 17 patients with angle-closure NVG were treated with intravitreous injection of Lucentis 0.50mg/0.05ml.Trabeculectomy were performed in 8~14 days with MMC application.The regression of iris neovascularization and changes in intraocular pressure ( IOP) were observed after the injection.Best corrected visual acuity was followed after trabeculectomy .Patients were followed-up for 8~12 months. Results Iris neovascularization completely regressed within one week in 13 eyes and within 2 weeks in the other 4 eyes af-ter the injection of Lucentis.The average IOP was (39.56 ±10.12) mm Hg before injection, and (38.62 ±8.35) mm-Hg in a week after injection.The IOP had no significant changes before and after injection ( t =0.951, P >0.05).The IOP was (10.43 ±6.12) mmHg in one week after trabeculectomy , and (13.61 ±4.31) mmHg in the last follow-up vis-it.Compared with the preoperative measurements , there was a significant reduction in IOP ( t =21.362 at 1 week, t =19.817 at 2 weeks, both P <0.01).The best corrected visual acuity improved in 12 eyes, remained unchanged in 5 eyes at last follow-up visit.Conclusion Intravitreous injection of Lucentis combined with trabeculectomy and MMC application could effectively control the IOP and preserve the visual function in patients with neovascular glaucoma .
